-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18

Benzinga·11/03/2026 13:25:24
Listen to the news
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and lowers the price target from $19 to $18.